Overview

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Status:
RECRUITING

Trial end date:
2030-11-08

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).

Phase:

PHASE3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

bimekizumab
Ustekinumab